Market Access News | pharmaphorum

News

NICE backs pump-based Parkinson’s drug from AbbVie

A therapy for Parkinson’s disease that can be delivered by a 24-hour subcutaneous infusion pump has been recommended for use by the NHS and could be an option for hundreds

News

FDA clears Servier's Tibsovo as first targeted drug for MDS

Servier has become the first company to get US approval for an IDH inhibitor as a treatment for myelodysplastic syndromes (MDS) after its Tibsovo drug was cleared by the F

News

AZ seeks FDA okay for first self-administered flu vaccine

The FDA has started a review of an extension to the labelling for AstraZeneca’s influenza vaccine FluMist Quadrivalent which would allow it to be administered by patients

News

Ipsen to refile Alagille drug after EU blocks orphan status

Ipsen has said that it plans to file a new marketing application for its treatment for itch in Alagille syndrome (ALGS), Bylvay, after failing to persuade an EMA committee

News

Pfizer sets Paxlovid price at nearly $1,400 per course

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year

News

UCB bags FDA approval for second myasthenia gravis drug

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hope

NICE backs pump-based Parkinson’s drug from AbbVie

FDA clears Servier's Tibsovo as first targeted drug for MDS

AZ seeks FDA okay for first self-administered flu vaccine

Ipsen to refile Alagille drug after EU blocks orphan status

Pfizer sets Paxlovid price at nearly $1,400 per course

UCB bags FDA approval for second myasthenia gravis drug

J&J's oral IL-23 drug backed for psoriasis in EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks